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Abstract
Electronic nicotine delivery systems (ENDS) are growing in use and many of the health implications with these devices remain
unknown. This study aims to assess, using a survey representative of the USA general population, if an association exists between a
history of ENDS use and a history of stroke.
This cross-sectional study was a secondary data analysis using the 2016 behavioral risk factor surveillance system survey. The
main exposure variable of the study was a self-reported history of ENDS use. Themain outcomewas a self-reported history of stroke.
Covariates included sex, race, traditional cigarette use, smokeless tobacco use, chronic kidney disease, diabetes, myocardial
infarction, and coronary artery disease. Unadjusted and adjusted logistic regression analyses were done. Adjusted odds ratios (AOR)
and their corresponding 95% confidence intervals (CI) were calculated.
Of the 486,303 total behavioral risk factor surveillance system survey participants, 465,594 met the inclusion criteria for this study
of ENDS use and stroke. This study shows that current ENDS use was positively associated with a history of stroke. AOR of some
daily ENDS use with stroke was 1.28 (95% CI: 1.02–1.61) and AOR of current daily ENDS use with stroke was 1.62 (95% CI: 1.18–
2.31). The majority (55.9%) of current daily ENDS users reported former traditional cigarette smoking. Female sex, non-white
ethnicity, elderly age, chronic kidney disease, coronary artery disease, diabetes, and traditional cigarette use characteristics were all
also associated with increased odds of reporting a stroke.
This study found a statistically significant and positive association between ENDS use and a history of stroke. Further research is
warranted to investigate the reproducibility and temporality of this association. Nevertheless, this study contributes to the growing
body of knowledge about the potential cardiovascular concerns related to ENDS use and the need for large cohort studies.
Abbreviations: AOR = adjusted odds ratio, BMI = body mass index, BRFSS = behavioral risk factor surveillance system, CAD =
coronary artery disease, CDC = Centers for Disease Control, CKD = chronic kidney disease, CVD = cardiovascular disease, DM =
diabetes mellitus, EDU = every day ENDS use, ENDS = electronic nicotine delivery systems, FU = former ENDS use, MACE =major
adverse cardiac events, NU = never ENDS use, SDU = nondaily ENDS use, TC = traditional cigarettes.
Keywords:association, behavioral risk factor surveillance system, cerebrovascular, electronic cigarette, electronic nicotine delivery
systems, stroke
1. Introduction
Electronic nicotine delivery systems (ENDS) have grown in
popularity as an alternative to the known harmful effects of
traditional cigarettes (TC). ENDS are especially growing amongst
teenagers, with one study finding that from 2011 to 2018 ENDS
use had grown from 1.5% to 20.8% of teenagers.[1–4] Yet, little is
known about long term health effects of ENDS, including effects
on cerebrovascular disease. In 2018, there were 147,810 fatal
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strokes in the United States, and stroke was the fifth most
common cause of death.[5] Per the American Heart Association
2021 Update on heart disease and stroke statistics, “the
cardiovascular disease (CVD) risks associated with e-cigarette
use are not known.”[5]
Several theoretical frameworks exist that could make ENDS a
possible risk factor for stroke. First, TCs have been found to be
major risk factor for stroke with many studies demonstrating a 2
to 4 times increased risk.[6–8] While considered by some studies to
be less toxic than TCs, ENDS share some similarities to them
including nicotine, inhalation at high temperatures, and some
overlap in ingested chemicals.[9,10] Substances such as acrolein
and formaldehyde, emitted in both TCs and ENDS, have been
associated with cardiotoxicity in rodents ranging from brady-
cardia to cardiomyopathy.[11,12] Second, numerous studies have
evaluated possible biochemical mechanisms which may link
ENDS to CVD and neural disease.[13–15] For example, ENDS
may have transient effects on increasing heart rate.[16] Its aerosol
contents may cause reactive damage and inflammation or impair
platelet function.[17,18] Albeit less than TCs, one study found
ENDS to increase unfavorable markers of vascular function
including oxidative stress and flow-mediated dilation.[18] Its use
may impair glucose uptake in the ischemic brain.[19]
Some population based cross-sectional studies have looked
into ENDS use and cardiovascular diseases. At least 2 studies
have found an association between ENDS use and myocardial
infarction.[20,21] However, the data for ENDS use and stroke are
particularly limited with 1 study in young adults thus far not
showing an overall association.[22] Thus, using a large US
population-based survey, the objective of this study (Study) is to
investigate if there is a statistical association between ENDS use
and stroke history.
2. Methods
2.1. Study design and population
This cross-sectional studywas a secondary data analysis using the
2016 Centers for Disease Control (CDC)’s behavioral risk factor
surveillance system (BRFSS). The CDC conducts the BRFSS
surveys annually in the general American population. Through-
out 2016, CDC interviewers collected data through a series of
randomized phone calls to landlines and cellular phones across all
50 states, Puerto Rico, District of Columbia, and the US Virgin
Islands.[23] In a standardized script, interviewers asked inter-
viewees a series of questions. Interviews took an average of 27
minutes.[23] The sampled population interviewed was designed
and statistically weighted by the BRFSS to have similar baseline
characteristics to the general American population. This Study’s
authors downloaded the publicly available data in 2018 from the
BRFSS section within the CDCs website.
This study includes patients only if they answered all of the
following questions from the 2016 BRFSS questionnaire.[24] For
Question 6.3, participants were asked: “Were you ever told that
you had a stroke?” Participants must have answered “yes” or
“no.” For Question 10.1, they were asked, have you ever used an
electronic cigarette product. For Question 10.2, they were also
asked: “Do you now use electronic cigarette or other electronic
‘vaping’ products every day, some days, or not at all?”
Participants must have answered “yes” or “no” to 10.1. If
participants answered “yes” to 10.1, they must have answered
“every day,” “some days,” or “not at all” to 10.2. Participants
were excluded from the study if they answered “don’t know/not
sure” or “refuse to answer” to any of the above questions
regarding ENDS use or stroke. A participant was still included in
the study if they answered appropriately to ENDS use and stroke
but answered “don’t know/not sure” or “refuse to answer” to
any of the 9 covariates: sex, age, race, body mass index (BMI),
coronary artery disease (CAD), chronic kidney disease (CKD),
diabetes mellitus (DM), smokeless tobacco use, and TC use.
Missing data points from unanswered covariate data were
excluded from this Study’s multivariate analysis.
2.2. Criteria for assessing data
The main independent variable of this study was self-reported
ENDS use, defined as electronic cigarettes and other electronic
“vaping” products including electronic hookas, vape pens,
e-cigars, and others. ENDS use was categorized as “current
every-day use (EDU),” “nondaily or some-days use (SDU),”
“former use (FU),” and “never use (NU).” FU was defined as
having used ENDS in the past but not currently using. The
dependent variable, and main outcome variable, is a self-reported
history of stroke, reported as “yes” or “no.”
This study evaluated the 9 covariates (sex, age, race, BMI, CAD,
CKD,DM, smokeless tobaccouse, andTCuse) as follows. Sexwas
defined as “male” or “female.” Age was categorized as “18–24,”
“25–34,” “35–44,” “45–54,” “55–64,” and “65+.” Race was
categorized as “non-Hispanic white” and “other,”which included
African American, Asian American, Hispanic, or other. Self-
reported BMI was categorized as “<25” or non-overweight, and
“≥25” or overweight in accordance with CDC guidelines.[25] Self-
reported diagnoses of CAD, CKD, and DM were categorized as
“yes” or “no.” Smokeless tobacco was differentiated as “current
use” versus “not current use.” “Current use” encompassed
participants who answered “every day” and “some day” use. TC
use was categorized into the following categories: “current-every
day,” “some-days,” “former,” and “never.” “Former” TC use
encompassedhaving smokedat least 100cigarettes inone’s life, but
none currently. If<100 lifetime TCs were used, and not currently
using, they were categorized as “never.”
This study analyzed the BRFSS data using STATA 3D.[26]
Initially, a descriptive analysis was performed to assess baseline
characteristics of ENDS use with covariates and stroke. Then,
analysis of variance testing was used to obtain P-values across
each category. Next, collinearity diagnostics were done to ensure
that none of the independent variables or covariates were
correlated with each other (r>0.6 or r<–0.6). Finally, logistic
regression analyses were performed to calculate unadjusted and
adjusted odds ratios (AOR) and their corresponding 95%
confidence intervals (CI).
2.3. Ethical considerations
This study used de-identified data and was classified by the
Florida International University Internal Review Board as non-
human subject research. The authors have no conflicts of interest
to disclose. The research was performed without any funding.
3. Results
This study’s population included 465,594 (95.7%) of the 2016
BRFSS survey of 486,303 participants. It excluded 20,709
(4.3%) participants due to missing data on history of stroke or
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ENDS usage. Within this study’s population, 5010 (1.5%)
participants reported EDU, 10,169 (3.0%) reported SDU, 58,834
(17.1%) reported FU, and 391,581 (78.4%) reported NU.
20,045 (3.2%) reported a history of stroke, and 445,549 (96.8%)
denied a history of stroke.
Table 1 outlines the baseline characteristics of ENDS use in this
study. Participants with stroke histories represented 3.5% of
total EDU versus 3.3% of total SDU versus 2.8% of total FU
versus 3.3% of total NU (P= .02). Demographically, EDU was
more associated with male sex, non-Hispanic white race, and
younger age compared with NU. Men accounted for 64.5% of
EDU versus 46.5% of NU (P< .01). Eighteen to 24-year-olds
accounted for 21.2% of EDU versus 9.6% of NU, while 65+
participants made up just 5.3% of EDU versus 24.1% of NU
(P< .01). Non-Hispanic Whites represented 79.1% of EDU but
only 63.0% of NU. Participants with EDU were less likely than
with NU to suffer from comorbidities including BMI≥25kg/m2,
CAD, and DM. BMI≥25 was seen in 63.4% of EDU versus
66.1% of NU (P< .01). CAD accounted for 5.4% of EDU
versus 7% of NU (P< .01). Likewise, DM was with 7.5% of
EDU versus 11.9% of NU (P< .01). CKD, however, was
recorded with 3.5% of EDU, 2.3% of SDU, 2.2% of FU, and
3.1% of NU (P< .01). Regarding tobacco, current daily TC use
was seen with 18% of EDU versus 4.8% of NU (P< .01). Of
note, the 55.9% of EDUwas seen with former TC use. Currently
smokeless tobacco use was seen in 6.4% of EDU versus 2.8% of
NU (P< .01).
Table 2 shows the adjusted odds ratios (AOR) between the
covariates and a history of stroke. Among demographic
covariates, female sex was positively associated with a history
of stroke versus men (AOR: 1.2, [95% CI: 1.1–1.3]). “Other”
race was also positively associated versus non-Hispanic white
(1.2, [1.1–1.3]). With age 25 to 34 chosen as the reference, age
>65 was strongly associated with stroke (7.3, [5.7–9.3]). Among
demographic covariates, BMI≥25 was not significantly associ-
ated with stroke versus a normal BMI (0.98, [0.90–1.05]).
However, reporting a history of CKD (2.1, [1.8–2.3]), CAD (4.3,
[3.9–4.6]), and DM (1.8, [1.6–1.9]) were all associated with a
stroke history. Within tobacco covariates, current every-day TC
use (2.1, [1.9–2.4]), current someday TC use (1.8, [1.6–2.1]), and
former TC use (1.3, [1.2–1.4]) were associated with stroke versus
never TC use. In this sample, current smokeless tobacco use was
not statistically associated with stroke versus non-current use
(1.2, [0.997–1.5]).
Table 1
Baseline characteristics of 2016 BRFSS participants according to electronic nicotine delivery system use.
Electronic nicotine delivery system use
Characteristic Current every day Current some day Former Never P value
∗
N % N % N % N %
Sex <.01
Male 2778 64.5 5018 57.8 29014 55.6 164605 46.5
Female 2229 35.5 5151 42.2 29815 44.4 226937 53.5
Race <.01
Non-Hispanic White 4109 79.1 7658 68.2 44074 66.3 298948 63
Othera 818 20.9 2357 31.8 13791 33.7 86135 37
Age, y <.01
18–24 640 21.2 1681 28.3 7972 23.6 15029 9.6
25–34 1030 28.3 1897 23.4 12373 27.5 30815 14.6
35–44 873 17.9 1536 17.5 9235 17.2 40707 15.9
45–54 900 15.9 1873 15 10281 14.7 60616 17.7
55–64 953 11.5 2050 11.3 11259 11.3 88737 18.3
65+ 614 5.3 1132 4.5 7714 5.8 155677 24.1
Body mass index, kg/m2 <.01
>25 3113 63.4 5957 58.6 35341 60.9 245605 66.1
<25 1710 36.6 3817 41.4 20733 39.1 119420 33.9
Kidney disease <.01
Yes 177 3.5 342 2.3 1828 2.2 15306 3.1
No 4812 96.5 9789 97.7 56833 97.8 375153 96.9
Coronary artery disease <.01
Yes 416 5.4 872 5.4 4877 5.4 37152 7
No 4561 94.6 9214 94.6 53529 94.6 351482 93
Diabetes <.01
Yes 473 7.5 1019 7 5759 6.8 56145 11.9
No 4528 92.5 9128 93 52978 93.2 334941 88.1
Traditional cigarette <.01
Current every day 1031 18 4849 41.3 23533 34 19342 4.8
Current some days 705 16.2 2158 20.9 7348 12.4 9331 2.8
Former 2878 55.9 1612 15.2 13970 22.5 115336 24.5
Never 375 9.8 1497 22.5 13698 31 245427 67.9
Smokeless tobacco <.01
Yes 271 6.4 751 8.1 3646 6.3 10498 2.8
No 4732 93.6 9400 91.9 55113 93.7 380506 97.2
a Hispanic White, African American, Asian American, and other.
∗
P value: performed by chi-squared test.
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Table 3 demonstrates the primary endpoint, the association
between ENDS use and stroke history. After adjusting for the 9
covariates above, EDU use was independently, positively
associated with stroke versus NU (1.62, [1.18–2.31]). SDU use
was also positively associated (1.28, [1.02–1.61]). FU was not
significantly associated with stroke (AOR 1.09, [0.98–1.23]).
4. Discussion
The data from this study revealed a positive association between
ENDS use and a history of stroke. EDU and SDU were both
associated with an increased likelihood compared with NU of
reporting stroke. The association with EDU was greater than
with SDU consistent with a dose dependent relationship.
Overall, this study’s associations between covariates and
stroke aligned relatively closely to those found in other large
population-based studies with differences sometimes in the
magnitude of the AORs. Female sex, old age, non-Caucasian
race, DM, CKD, and TC use have all been accepted as risk factors
for stroke.[5] This study’s female sex association is very similar to
the Framingham study which noted a 1 in 5 lifelong risk of stroke
for women versus 1 in 6 for men.[27] For race, this study echoes
Table 2
Unadjusted and adjusted odds ratios between covariates and a history of stroke using the 2016 BRFSS survey.
History of stroke
Covariate Unadjusted Adjusted
OR (95% CI) P-value OR (95% CI) P-value
Sex
Male Reference Reference
Female 1.03 (0.97–1.09) .37 1.2 (1.1–1.3) <.01
Race
Non-Hispanic White Reference Reference
Othera 0.8 (0.76–0.88) <.01 1.2 (1.1–1.3) <.01
Age
25–34 Reference Reference
18–24 0.4 (0.2–0.7) .04 0.5 (0.3–0.95) .03
35–44 1.9 (1.5–2.5) <.01 2.0 (1.5–2.6) <.01
45–54 3.6 (2.9–4.5) <.01 3.2 (2.5–4.1) <.01
55–64 6.0 (4.9–7.5) <.01 4.7 (3.7–6.0) <.01
65+ 10.4 (8.4–12.8) <.01 7.3 (5.7–9.3) <.01
Body mass index, kg/m2
<25 Reference Reference
≥25 1.3 (1.2–1.4) <.01 0.98 (0.90–1.05) .52
Kidney disease
No Reference Reference
Yes 5.1 (4.6–5.6) <.01 2.1 (1.8–2.3) <.01
Coronary artery disease
No Reference Reference
Yes 9.1 (8.5–9.7) <.01 4.3 (3.9–4.6) <.01
Diabetes
No Reference Reference
Yes 4.1 (3.8–4.3) <.01 1.8 (1.6–1.9) <.01
Traditional cigarette
Never Reference Reference
Current every day 2.4 (2.2–2.6) <.01 2.1 (1.9–2.4) <.01
Current some days 1.8 (1.6–2.0) <.01 1.8 (1.6–2.1) <.01
Former 2.2 (2.0–2.3) <.01 1.3 (1.2–1.4) <.01
Smokeless tobacco
No Reference Reference
Yes 1.07 (0.8–1.3) .49 1.2 (0.997–1.5) .053
a Other: Hispanic White, African American, Asian American, and other.
Table 3
Unadjusted and adjusted odds ratios of electronic nicotine delivery system (ENDS) use and a history of stroke using the 2016 BRFSS
survey.
Stroke
ENDS use Unadjusted Adjusted
OR (95% CI) P-value OR (95% CI) P-value
Never Reference Reference
Current everyday 1.08 (0.80–1.47) .61 1.62 (1.18–2.31) .01
Current some days 1.02 (0.84–1.24) .84 1.28 (1.02–1.61) .03
Former 0.86 (0.79–0.94) <.01 1.09 (0.98–1.23) .11
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other studies with non-Caucasian race as a risk factor.[28–30]
However, this study’s strength of association was less than in the
REGARDS cohort, which compared stroke to black versus white
ethnicity.[28] This study found that diabetes nearly doubled the
risk of reporting stroke, similar to a prior study consisting of
775,385 people.[31] Most studies showed that reduced glomeru-
lar filtration rate was associated with an increased odds of
reporting stroke, however this study’s associations were stronger
than in some other studies.[32–34] A meta analysis with 280,000
pooled patients found a lower risk ratio.[32] This study did not
account for hypertension which may overestimate this AOR
compared with the other studies which were able to account for
it. Finally, this study found daily TC use to double the odds of
reporting stroke, in line with previous research.[6–8] Overall, the
similarity of this study’s multifactorial analysis of covariates to
stroke compared with those reported in other large studies adds
validity to this study’s key finding of a statistically significant
association between ENDS use and stroke.
Furthermore, several cross-sectional based studies have looked
at the association between ENDS andmyocardial infarction. One
2018 study of 70,000 participants using the National Health
Interview Surveys found that current ENDS users had a
statistically significant increased odds of reporting an MI
compared with NUs (AOR=1.8; 95% CI 1.2–2.7).[20] A second
study published in 2019, looking at about 60,000 participants in
the 2016 to 2017 National Health Interview Surveys, found no
statistically significant association between daily ENDS use and
MI (AOR 1.35, 95%CI: 0.80–2.27).[21] While their study did not
find statistical significance, only 714 participants reported EDU,
compared with this Study of which 5010 reported EDU. It is
possible that if a larger sample was used, statistical significance
would have been found. This study found a large association
between MI and stroke. The positive associations found between
ENDS andMI bolster the possibility of a true association between
ENDS and stroke due to overlaps in pathogenesis between MI
and stroke.
Finally, one recently published study using pooled data from
the 2016 to 2017 BRFSS sought to examine the risk of stroke with
ENDS use in young adults.[22] Amongst 150,000 participants
aged 18 to 44, their results found that dual use of ENDS and TCs
was associated with a 2.91 AOR (1.62–5.25) of stroke versus
nonusers, and a 1.83 AOR (1.06–3.17) of stroke with dual use
versus only TCs. Compared with nonsmokers, ENDS use did not
show significantly different odds of stroke versus non ENDS or
TC users (AOR 0.69, 0.34–1.32).[22] Parekh et al’s findings
differs from this study’s as their study examined at a younger
subset and utilized subgroup analyses to look at single ENDS use
and dual ENDS use with TC use. Meanwhile this study had a
different focus, to find a global independent association between
ENDS use and stroke, across all age groups. It included
participants of any adult age, including participants older than
65, who are far more likely to report a stroke.
Naturally, this study has some limitations. First, ENDS were
initially introduced around 2007 and this study’s data were
collected in 2016.[35] Hence, there is a relatively short time period
in which a person could have ingested enough ENDS doses for
ENDS to be a risk factor. Second, while this study accounted for 9
important covariates, it missed valuable modifiable risk factors
including hypertension, hyperlipidemia, and alcohol use. The
BRFSS did not include these variables in their 2016 question-
aire.[24] Third, this study lacked the resolution to further
differentiate levels of ENDS use beyond the categories of
“EDU,” “SDU,” and “FU.” “SDU” is a potentially vague
classification and might not precisely reflect ENDS use. Fourth
these data were self-reported which is subject its own inaccura-
cies.
Lastly, this study’s most important limitation is its cross-
sectional design. This study could not determine the temporality
of the association between ENDS use and a history of stroke.
Rather than ENDS use being the exposure variable, and a history
of stroke as the outcome variable as intended, it could be that a
history of stroke is a risk factor for a participant starting ENDS.
This Study found that most every day ENDS users are former TC
users and over 90% of every day ENDS users have smoked at
least 100 lifetime cigarettes. In other studies, such as the National
Center for Health Statistics data brief, among former TC users
who quit within the last year, 25.2% of them were current ENDS
users. Meanwhile, among current TC users, only 9.7% of them
were current ENDS users.[36] Similarly, current TC users with a
history of CVDwho attempted to quit TC use in the past year had
1.97 times the odds of current ENDS use compared with all TC
smokers (including the non-CVD population), who did not
attempt to quit TC use within the past year.[37] Some evidence has
suggested that TC users may be more prone to stop smoking TCs
after a major adverse cardiac event (MACE).[38,39]
However, whether TC users after MACE actually switch to
ENDS in a greater frequency than patients without MACE
remains to be proven. One study, using 2013 to 2015 Population
Assessment of Tobacco andHealth data, determined that postMI
patients who smoked TCs were not significantly more likely to
adopt non-combustible cigarettes than those without an MI.[40]
Nevertheless, even if stroke and other MACE were found to be
independent risk factors for ENDS, this would still have
important healthcare implications. The FDA has yet to approve
ENDS for smoking cessation, let alone in those with MACE.
The CDC and American Heart Association lack clear statements
on ENDS use in patients after MACE, such as stroke.
This study’s positive association could be due to either ENDS
use as the exposure with stroke as the outcome, or stroke as the
exposure with ENDS use as the outcome—both scenarios with
important public health implications. The validity of this study’s
positive association is supported by the similarity of this study’s
covariates to stroke AORs versus the AORs found in other large
studies. It is further supported by the existence of reported
positive associations between ENDS use and CAD found in a
recent study. Thus, this study’s statistical association cannot be
ignored and its existence compels the need for future cohort
studies to best analyze a relationship between ENDS use and
stroke.
5. Conclusion
This study, consisting of over 450,000 people responding to the
2016 BRFSS survey, found an independent positive association
between ENDS use and stroke. It is among the first population-
based studies to assess for this association. Further research,
particularly cohort studies, is needed to assess the reproducibility
and temporality of the positive association found in this study.
Author contributions
Conceptualization: Ryan Aziz Thomas Bricknell, Christobal
Ducaud, Alejandra Figueroa, Juan Carlos Zevallos, Noël C.
Barengo.
Bricknell et al. Medicine (2021) 100:36 www.md-journal.com
5
Data curation: Ryan Aziz Thomas Bricknell, Christobal Ducaud,
Alejandra Figueroa, Pura Rodriguez, Grettel Castro.
Formal analysis: Ryan Aziz Thomas Bricknell, Christobal
Ducaud, Alejandra Figueroa, Pura Rodriguez, Grettel Castro.
Investigation: Ryan Aziz Thomas Bricknell, Christobal Ducaud,
Alejandra Figueroa, Logan S. Schwarzman, Juan Carlos
Zevallos, Noël C. Barengo.
Methodology: Ryan Aziz Thomas Bricknell, Christobal Ducaud,
Alejandra Figueroa, Pura Rodriguez, Grettel Castro, Juan
Carlos Zevallos, Noël C. Barengo.
Project administration: Ryan Aziz Thomas Bricknell, Christobal
Ducaud, Juan Carlos Zevallos, Noël C. Barengo.
Resources: Ryan Aziz Thomas Bricknell, Alejandra Figueroa,
Noël C. Barengo.
Software: Ryan Aziz Thomas Bricknell, Christobal Ducaud,
Alejandra Figueroa, Pura Rodriguez, Grettel Castro.
Supervision: Juan Carlos Zevallos, Noël C. Barengo.
Validation: Ryan Aziz Thomas Bricknell.
Visualization: Ryan Aziz Thomas Bricknell, Noël C. Barengo.
Writing – original draft: Ryan Aziz Thomas Bricknell, Logan S.
Schwarzman.
Writing – review & editing: Ryan Aziz Thomas Bricknell, Logan
S. Schwarzman, Noël C. Barengo.
References
[1] Cullen KA, Ambrose BK, Gentzke AS, Apelberg BJ, Jamal A, King BA.
Notes from the field: use of electronic cigarettes and any tobacco product
among middle and high school students—United States, 2011–2018.
Morb Mortal Wkly Rep 2018;67:1276.
[2] Murthy VH. E-cigarette use among youth and young adults: a major
public health concern. JAMA Pediatr 2017;171:209–10.
[3] Walley SC, Wilson KM, Winickoff JP, Groner J. A public health crisis:
electronic cigarettes, vape, and JUUL. Pediatrics 2019;143:e20182741.
[4] Glasser AM, Collins L, Pearson JL, et al. Overview of electronic nicotine
delivery systems: a systematic review. Am J Prev Med 2017;52:e33–66.
[5] Virani SS, Alonso A, Aparicio HJ, et al. Heart Disease and Stroke
Statistics—2021 update: a report from the American Heart Association.
Circulation 2021;143:e254–743.
[6] Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-
related mortality in the United States. N Engl J Med 2013;368:351–64.
[7] Ohira T, Shahar E, Chambless LE, Rosamond WD, Mosley THJr,
Folsom AR. Risk factors for ischemic stroke subtypes: the Atherosclero-
sis Risk in Communities study. Stroke 2006;37:2493–8.
[8] Frishman W. Tobacco use and risk of myocardial infarction in 52
countries in the INTERHEART study: a case-control study. Yearb Med
2007;2007:313–5.
[9] Cheng T. Chemical evaluation of electronic cigarettes. Tob Control
2014;23(suppl):ii11–7.
[10] Margham J, McAdam K, Forster M, et al. Chemical composition of
aerosol from an e-cigarette: a quantitative comparison with cigarette
smoke. Chem Res Toxicol 2016;29:1662–78.
[11] Horiguchi TT. Effects of formaldehyde on cardiac function. Jpn J
Pharmacol 1990;52:563–72.
[12] Henning RJ, Johnson GT, Coyle JP, Harbison RD. Acrolein can cause
cardiovascular disease: a review. Cardiovasc Toxicol 2017;17:227–36.
[13] Bhatnagar A. Cardiovascular perspective of the promises and perils of e-
cigarettes. Circ Res 2016;118:1872–5.
[14] QasimH, Karim ZA, Rivera JO, Khasawneh FT, Alshbool FZ. Impact of
electronic cigarettes on the cardiovascular system. J Am Heart Assoc
2017;6:e006353.
[15] MacDonald A, Middlekauff HR. Electronic cigarettes and cardiovascu-
lar health: what do we know so far? Vasc Health Risk Manag 2019;15:
159–74.
[16] Vansickel AR, Eissenberg T. Electronic cigarettes: effective nicotine
delivery after acute administration. Nicotine Tob Res 2012;15:267–70.
[17] Hom S, Chen L, Wang T, Ghebrehiwet B, Yin W, Rubenstein DA.
Platelet activation, adhesion, inflammation, and aggregation potential
are altered in the presence of electronic cigarette extracts of variable
nicotine concentrations. Platelets 2016;27:694–702.
[18] Carnevale R, Sciarretta S, Violi F, et al. Acute impact of tobacco vs
electronic cigarette smoking on oxidative stress and vascular function.
Chest 2016;150:606–12.
[19] Sifat AE, Vaidya B, Kaisar MA, Cucullo L, Abbruscato TJ. Nicotine and
electronic cigarette (E-Cig) exposure decreases brain glucose utilization
in ischemic stroke. J Neurochem 2018;147:204–21.
[20] Alzahrani T, Pena I, Temesgen N, Glantz SA. Association between
electronic cigarette use and myocardial infarction. Am J Prev Med
2018;55:455–61.
[21] Farsalinos KE, Polosa R, Cibella F, Niaura R. Is e-cigarette use associated
with coronary heart disease and myocardial infarction? Insights from the
2016 and 2017 National Health Interview Surveys. Therap Adv Chronic
Dis 2019;10:2040622319877741.
[22] Parekh T, Pemmasani S, Desai R. Risk of stroke with e-cigarette
and combustible cigarette use in young adults. Am J Prev Med
2020;58:446–52.
[23] Behavioral Risk Factor Surveillance System OVERVIEW: BRFSS 2016.
Center for Disease Control; 2017.
[24] Behavioral Risk Factor Surveillance System Questionnaire: BRFSS 2016.
Center for Disease Control; 2015.
[25] Defining Adult Overweight and Obesity. Center for Disease Control and
Prevention; 2017.
[26] Behavioral Risk Factor Surveillance System LLCP 2016 Codebook
Report: BRFSS 2016. Center for Disease Control; 2017.
[27] Seshadri S, Beiser A, Kelly-Hayes M, et al. The lifetime risk of stroke:
estimates from the Framingham Study. Stroke 2006;37:345–50.
[28] Howard VJ, Kleindorfer DO, Judd SE, et al. Disparities in stroke
incidence contributing to disparities in stroke mortality. Ann Neurol
2011;69:619–27.
[29] Morgenstern LB, SmithMA, Lisabeth LD, et al. Excess stroke inMexican
Americans compared with non-Hispanic whites: the brain attack
surveillance in Corpus Christi project. Am J Epidemiol
2004;160:376–83.
[30] White H, Boden-Albala B, Wang C, et al. Ischemic stroke subtype
incidence amongwhites, blacks, andHispanics: the NorthernManhattan
Study. Circulation 2005;111:1327–31.
[31] Peters SA, Huxley RR,WoodwardM. Diabetes as risk factor for incident
coronary heart disease in women compared with men: a systematic
review and meta-analysis of 64 cohorts including 858,507 individuals
and 28,203 coronary events. Diabetologia 2014;57:1542–51.
[32] Lee M, Saver JL, Chang KH, Liao HW, Chang SC, Ovbiagele B. Low
glomerular filtration rate and risk of stroke: meta-analysis. BMJ
2010;341:c4249.
[33] Mahmoodi BK, Yatsuya H, Matsushita K, et al. Association of kidney
disease measures with ischemic versus hemorrhagic strokes: pooled
analyses of 4 prospective community-based cohorts. Stroke
2014;45:1925–31.
[34] WangX,Wang Y, Patel UD, et al. Comparison of associations of reduced
estimated glomerular filtration rate with stroke outcomes between
hypertension and no hypertension. Stroke 2017;48:1691–4.
[35] Romeh F, Diaz M, Vallone D. E-cigarette Unit Sales, by Product and
Flavor Type - United States, 2014–2020. Centers for Disease Control and
Prevention; 2020.
[36] VillarroelMA, Cha AE, Vahratian A. Electronic cigarette use among U.S.
adults, 2018. NCHS Data Brief, no 365. Hyattsville, MD: National
Center for Health Statistics; 2020.
[37] Stokes A, Collins JM, Berry KM, et al. Electronic cigarette prevalence and
patterns of use in adults with a history of cardiovascular disease in the
United States. J Am Heart Assoc 2018;7:e007602.
[38] Streck JM, Chang Y, Tindle HA, et al. Smoking cessation after hospital
discharge: factors associated with abstinence. J Hosp Med 2018;13:774.
[39] HolmM, Schiöler L, Andersson E, et al. Predictors of smoking cessation:
a longitudinal study in a large cohort of smokers. Respir Med
2017;132:164–9.
[40] Gaalema DE, Pericot-Valverde I, Bunn JY, et al. Tobacco use in cardiac
patients: Perceptions, use, and changes after a recent myocardial
infarction among US adults in the PATH study (2013-2015). Prev
Med 2018;117:76–82.
Bricknell et al. Medicine (2021) 100:36 Medicine
6
